Base de dados : MEDLINE
Pesquisa : D02.886.640.074 [Categoria DeCS]
Referências encontradas : 3559 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 356 ir para página                         

  1 / 3559 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29406029
[Au] Autor:Elkady EF; Fouad MA; Jaadan BM
[Ad] Endereço:Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt.
[Ti] Título:LC-MS/MS bioassay of four proton pump inhibitors.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1076:61-69, 2018 Feb 15.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A new validated bio-analytical LC-MS/MS method was developed for the simultaneous extraction and determination of four proton pump inhibitors: esomeprazole, lansoprazole, pantoprazole and rabeprazole in human plasma using escitalopram as an internal standard. The proteins in plasma samples were precipitated using acetonitrile for the extraction of analytes which is a simple economic method. The separation was accomplished using a mobile phase composed of 10 mM ammonium formate: acetonitrile: methanol (20:40:40% v/v) at a flow rate of 0.8 mL/min in isocratic mode on a reversed phase C18 INERTSIL ODS-3 (5 µm, 150 × 4.6 mm) and column temperature of 40 °C. Positive mode electrospray ionization source was used prior to multiple reaction monitoring (MRM) detection using parent and daughter ions: m/z 346.2 → 198.1 for esomeprazole, m/z 370.1 → 252 for lansoprazole, m/z 384.2 → 200.2 for pantoprazole, m/z 360.1 → 242.1 for rabeprazole and m/z 325.2 → 109 for escitalopram. The calibration curves were constructed, and the method was linear in the range of 20-5000 ng/mL applying weighted (1/X ) linear regression coefficient for all drugs. The method was fully validated following US-FDA and EMA guidelines.
[Mh] Termos MeSH primário: 2-Piridinilmetilsulfinilbenzimidazóis/sangue
Cromatografia Líquida/métodos
Inibidores da Bomba de Prótons/sangue
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Modelos Lineares
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Proton Pump Inhibitors)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  2 / 3559 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29391326
[Au] Autor:Karakan T
[Ad] Endereço:Department of Gastroenterology, Gazi University School of Medicine, Ankara, Turkey.
[Ti] Título:Use of Proton Pump Inhibitors and risk of gastric cancer.
[So] Source:Turk J Gastroenterol;29(1):141-142, 2018 01.
[Is] ISSN:2148-5607
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Bomba de Prótons
Neoplasias Gástricas
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis
Antiulcerosos
Ácido Gástrico
Seres Humanos
Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Anti-Ulcer Agents); 0 (Proton Pump Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.5152/tjg.2018.17002


  3 / 3559 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28459708
[Au] Autor:Alhazzani W; Guyatt G; Alshahrani M; Deane AM; Marshall JC; Hall R; Muscedere J; English SW; Lauzier F; Thabane L; Arabi YM; Karachi T; Rochwerg B; Finfer S; Daneman N; Alshamsi F; Zytaruk N; Heel-Ansdell D; Cook D; Canadian Critical Care Trials Group
[Ad] Endereço:1Department of Medicine, McMaster University, Hamilton, ON, Canada.2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.3Department of Critical Care, University of Dammam, Dammam, Saudi Arabia.4Discipline of Acute Care Medicine, University of Adelaide, Adelaide, SA, Australia.5Department of Surgery and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.6Departments of Anesthesia, Pain Management and Perioperative Medicine and Critical Care Medicine, Dalhousie University, Halifax, NS, Canada.7Department of Critical Care, Queens University, Kingston, ON, Canada.8Department of Medicine (Critical Care), University of Ottawa, Ottawa, ON, Canada.9Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.10Departments of Medicine, Anesthesiology and Critical Care, Université Laval, Quebec City, QC, Canada.11Biostatistics Unit, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada.12Intensive Care Department, King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.13The George Institute for Global Health and Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.14Department of Medicine, University of Toronto, Toronto, ON, Canada.15Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates.
[Ti] Título:Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis.
[So] Source:Crit Care Med;45(7):1121-1129, 2017 Jul.
[Is] ISSN:1530-0293
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: A decreased frequency of upper gastrointestinal bleeding and a possible association of proton pump inhibitor use with Clostridium difficile and ventilator-associated pneumonia have raised concerns recently. The Reevaluating the Inhibition of Stress Erosions Pilot Trial determined the feasibility of undertaking a larger trial investigating the efficacy and safety of withholding proton pump inhibitors in critically ill patients. METHODS: In 10 ICUs, we randomized adult ICU patients anticipated to be mechanically ventilated for greater than or equal to 48 hours to receive 40 mg of IV pantoprazole daily or placebo. We excluded patients who had acute or recent gastrointestinal bleed, used dual antiplatelet agents, had a medical condition requiring proton pump inhibitor treatment, or had already received more than one dose of acid suppression daily. Patients, families, clinicians, and research staff were blinded. We conducted a systematic review and meta-analysis of similar trials. MAIN RESULTS: Ninety-one patients (49 pantoprazole and 42 placebo) from 10 centers in Canada, Saudi Arabia, and Australia were enrolled. All feasibility goals were met: 1) recruitment rate was 2.6 patients per month; 2) consent rate was 77.8%; and 3) protocol adherence was 97.7%. Upper gastrointestinal bleeding developed in 6.1% of patients in the pantoprazole group and 4.8% in the placebo group (p = 1.0). Ventilator-associated pneumonia developed in 20.4% of patients in the pantoprazole group and 14.3% in the placebo group (p = 0.58). C. difficile was identified in 4.1% pantoprazole patients and in 2.4% placebo patients (p = 1.0). We meta-analyzed five trials (604 patients) of proton pump inhibitors versus placebo; there was no statistically significant difference in the risk of upper gastrointestinal bleeding, infections, or mortality. CONCLUSIONS: Our results support the feasibility of a larger trial to evaluate the safety of withholding stress ulcer prophylaxis. Although the results are imprecise, there was no alarming increase in the risk of upper gastrointestinal bleeding; the effect of proton pump inhibitors on ventilator-associated pneumonia and C. difficile remain unclear.
[Mh] Termos MeSH primário: 2-Piridinilmetilsulfinilbenzimidazóis/efeitos adversos
Infecções por Clostridium/epidemiologia
Estado Terminal
Pneumonia Associada à Ventilação Mecânica/epidemiologia
Inibidores da Bomba de Prótons/efeitos adversos
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem
Adulto
Idoso
Método Duplo-Cego
Hemorragia Gastrointestinal/prevenção & controle
Seres Humanos
Unidades de Terapia Intensiva/estatística & dados numéricos
Meia-Idade
Projetos Piloto
Inibidores da Bomba de Prótons/administração & dosagem
Úlcera Gástrica/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Proton Pump Inhibitors); D8TST4O562 (pantoprazole)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171224
[Lr] Data última revisão:
171224
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1097/CCM.0000000000002461


  4 / 3559 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953640
[Au] Autor:Li MJ; Li Q; Sun M; Liu LQ
[Ad] Endereço:aSchool of Pharmacy, Shanxi Medical University bDepartment of Pharmacy, The First Hospital of Shanxi Medical University, Taiyuan cDepartment of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan dDepartment of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, P.R. China.
[Ti] Título:Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
[So] Source:Medicine (Baltimore);96(39):e8120, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg. METHODS: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study. RESULTS: For the NMA, eligible RCTs of adults with EE verified by endoscopic examination were randomly assigned to the licensed PPIs at least 4 weeks of continuous therapy. The primary efficacy outcome was the endoscopic healing rates at 4 and 8 weeks. Heartburn relief rates were a secondary efficacy outcome. The rates of withdrawal were analyzed as a safety outcome. In comparison to the common comparator omeprazole 20 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [odds ratio (OR), 1.46 (95% confidence interval, 95% CI, 1.24-1.71)] and 8 weeks [1.58 (1.29-1.92)], and improved the heartburn relief rates [1.29 (1.07-1.56)]. In comparison to lansoprazole 30 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [1.30 (1.10-1.53)] and 8 weeks [1.37 (1.13-1.67)], and improved the heartburn relief rates [1.29 (1.03-1.62)]. In terms of acceptability, only dexlansoprazole 60 mg had significantly more all-cause discontinuation than omeprazole 20 mg [1.54 (1.03-2.29)], pantoprazole 40 mg [1.68 (1.08-2.63)], and lansoprazole 30 mg [1.38 (1.02-1.88)]. CONCLUSION: The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief. Esomeprazole 40 mg, pantoprazole 40 mg, esomeprazole 20 mg, and lansoprazole 30 mg showed more benefits in effectiveness and acceptability than other interventions.
[Mh] Termos MeSH primário: Esofagite Péptica/tratamento farmacológico
Inibidores da Bomba de Prótons/administração & dosagem
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem
Adulto
Pesquisa Comparativa da Efetividade
Dexlansoprazol/administração & dosagem
Esomeprazol/administração & dosagem
Esofagite Péptica/complicações
Feminino
Azia/tratamento farmacológico
Azia/etiologia
Seres Humanos
Lansoprazol/administração & dosagem
Masculino
Meia-Idade
Metanálise em Rede
Omeprazol/administração & dosagem
Rabeprazol/administração & dosagem
Resultado do Tratamento
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 32828355LL (Rabeprazole); D8TST4O562 (pantoprazole); KG60484QX9 (Omeprazole); N3PA6559FT (Esomeprazole); UYE4T5I70X (Dexlansoprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008120


  5 / 3559 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28863169
[Au] Autor:Pokrzywa M; Pawelek K; Kucia WE; Sarbak S; Chorell E; Almqvist F; Wittung-Stafshede P
[Ad] Endereço:Airoptic Sp. z o.o., Poznan, Poland.
[Ti] Título:Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson's disease.
[So] Source:PLoS One;12(9):e0184117, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Alpha-synuclein (aS) amyloid formation is involved in Parkinson's disease (PD); therefore, small molecules that target aS and affect its aggregation are of interest as future drug candidates. We recently reported modified ring-fused 2-pyridones that modulate aS amyloid formation in vitro. Here, we describe the effects of such molecules on behavioral parameters of a Drosophila model of PD (i.e., flies expressing human aS), using a new approach (implemented in a commercially available FlyTracker system) to quantify fly mobility. FlyTracker allows for automated analysis of walking and climbing locomotor behavior, as it collects large sequences of data over time in an unbiased manner. We found that the molecules per se have no toxic or kinetic effects on normal flies. Feeding aS-expressing flies with the amyloid-promoting molecule FN075, remarkably, resulted in increased fly mobility at early time points; however, this effect switched to reduced mobility at later time points, and flies had shorter life spans than controls. In contrast, an amyloid inhibitor increased both fly kinetics and life span. In agreement with increased aS amyloid formation, the FN075-fed flies had less soluble aS, and in vitro aS-FN075 interactions stimulated aS amyloid formation. In addition to a new quantitative approach to probe mobility (available in FlyTracker), our results imply that aS regulates brain activity such that initial removal (here, by FN075-triggered assembly of aS) allows for increased fly mobility.
[Mh] Termos MeSH primário: Amiloide/química
Doença de Parkinson/metabolismo
alfa-Sinucleína/fisiologia
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis
Animais
Animais Geneticamente Modificados
Comportamento Animal
Encéfalo/patologia
Modelos Animais de Doenças
Drosophila melanogaster
Feminino
Seres Humanos
Levodopa/química
Locomoção
Atividade Motora
Doença de Parkinson/tratamento farmacológico
Doença de Parkinson/patologia
Piridonas/química
Proteínas Recombinantes/química
Espectroscopia de Infravermelho com Transformada de Fourier
alfa-Sinucleína/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Amyloid); 0 (Pyridones); 0 (Recombinant Proteins); 0 (alpha-Synuclein); 46627O600J (Levodopa)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170902
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184117


  6 / 3559 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28624580
[Au] Autor:Vanclooster A; van Deursen C; Jaspers R; Cassiman D; Koek G
[Ad] Endereço:Department of Gastroenterology-Hepatology and Metabolic Center, University Hospital Leuven, Belgium.
[Ti] Título:Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial.
[So] Source:Gastroenterology;153(3):678-680.e2, 2017 Sep.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Phlebotomy constitutes the established treatment for HFE-related hemochromatosis. Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population. We conducted a randomized controlled trial to prove this. Thirty p.C282Y homozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months. Phlebotomies were performed when serum ferritin was > 100 µg/L. Phlebotomy need turned out to be significantly lower in patients taking PPI (P = .0052). PPI treatment significantly reduces the need for phlebotomies in p.C282Y homozygous patients. In view of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy. Clinicaltrials.gov: NCT01524757.
[Mh] Termos MeSH primário: 2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico
Proteína da Hemocromatose/genética
Hemocromatose/genética
Hemocromatose/terapia
Inibidores da Bomba de Prótons/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Método Duplo-Cego
Feminino
Ferritinas/sangue
Hemocromatose/sangue
Homozigoto
Seres Humanos
Masculino
Meia-Idade
Flebotomia/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (HFE protein, human); 0 (Hemochromatosis Protein); 0 (Proton Pump Inhibitors); 9007-73-2 (Ferritins); D8TST4O562 (pantoprazole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170619
[St] Status:MEDLINE


  7 / 3559 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28603135
[Au] Autor:Lu M
[Ad] Endereço:Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
[Ti] Título:Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack.
[So] Source:Pak J Pharm Sci;30(1):217-221, 2017 Jan.
[Is] ISSN:1011-601X
[Cp] País de publicação:Pakistan
[La] Idioma:eng
[Ab] Resumo:The study aimed to investigate the impact of clopidogrel combined with proton pump inhibitors (PPI) pantoprazole treatment on the prognosis of patients with transient ischemic attack (TIA). A total of 478 cases of TIA patients treated with clopidogrel were randomly assigned half to clopidogrel combined with pantoprazole treatment and the control groups (clopidogrel treatment alone) from January 2012 to January 20l4. The platelet aggregation before and after treatment and cerebrovascular events incidence within 90 days were compared and analyzed. Multivariate analysis was used to estimate the incidence of cerebrovascular events within 90 days. The platelet aggregation rate before treatment was 73.2±6.1% in the treatment group, 74.1±8.8% in the control group. The platelet aggregation rate after treatment was 38.1±10.7% in the treatment group, 36.8±9.7% in the control group. The platelet aggregation before and after treatments between the two groups had not significant difference (P>0.05). The incidence of cerebrovascular events within 90 days (11.7% in the treatment group, 9.6% in the control group) between the two groups had not significant difference (P>0.05). Multivariate analysis showed that the incidence of cerebrovascular events within 90 day was associated with hypertension (P=0.008), diabetes (P=0.000), hyperlipidemia (P=0.002) and ABCD2 score >3 points (P=0.000). Clopidogrel combined with pantoprazole treatment had no significant effect on the prognosis of TIA patients.
[Mh] Termos MeSH primário: 2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico
Ataque Isquêmico Transitório/tratamento farmacológico
Inibidores da Agregação de Plaquetas/uso terapêutico
Agregação Plaquetária/efeitos dos fármacos
Inibidores da Bomba de Prótons/uso terapêutico
Acidente Vascular Cerebral/prevenção & controle
Ticlopidina/análogos & derivados
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/efeitos adversos
Idoso
Idoso de 80 Anos ou mais
Distribuição de Qui-Quadrado
China/epidemiologia
Citocromo P-450 CYP2C19/genética
Citocromo P-450 CYP2C19/metabolismo
Progressão da Doença
Quimioterapia Combinada
Feminino
Genótipo
Seres Humanos
Incidência
Ataque Isquêmico Transitório/sangue
Ataque Isquêmico Transitório/diagnóstico
Ataque Isquêmico Transitório/epidemiologia
Modelos Logísticos
Masculino
Meia-Idade
Análise Multivariada
Variantes Farmacogenômicos
Fenótipo
Inibidores da Agregação de Plaquetas/efeitos adversos
Testes de Função Plaquetária
Inibidores da Bomba de Prótons/efeitos adversos
Fatores de Risco
Acidente Vascular Cerebral/sangue
Acidente Vascular Cerebral/diagnóstico
Acidente Vascular Cerebral/epidemiologia
Ticlopidina/efeitos adversos
Ticlopidina/uso terapêutico
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Platelet Aggregation Inhibitors); 0 (Proton Pump Inhibitors); A74586SNO7 (clopidogrel); D8TST4O562 (pantoprazole); EC 1.14.14.1 (CYP2C19 protein, human); EC 1.14.14.1 (Cytochrome P-450 CYP2C19); OM90ZUW7M1 (Ticlopidine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE


  8 / 3559 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28415523
[Au] Autor:Khashaba PY; Ali HRH; El-Wekil MM
[Ad] Endereço:Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut University, Egypt; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Deraya University, El-Minya, Egypt.
[Ti] Título:Simultaneous voltammetric analysis of anti-ulcer and D -antagonist agents in binary mixture using redox sensor and their determination in human serum.
[So] Source:Mater Sci Eng C Mater Biol Appl;75:733-741, 2017 Jun 01.
[Is] ISSN:1873-0191
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Pencil graphite electrode was successfully modified with a thin film of poly (eriochrome black T) and applied for the sensitive and selective voltammetric simultaneous determination of pantoprazole sodium and domperidone in a binary mixture. The preparation and basic electrochemical behavior of poly (eriochrome black T) film on the Pencil graphite electrode were investigated. The modified electrode has exhibited very high electro-catalytic activity towards the cited mixture. The anodic peaks of the both species were well defined with enhanced oxidation peak currents. Under the optimum conditions, the linearity ranges were 0.4-55×10 M and 0.1-34×10 M for pantoprazole sodium and domperidone, respectively with detection limits of 0.12×10 M and 0.04×10 M for pantoprazole sodium and domperidone, respectively. The proposed sensor has been successfully applied in the analysis of pantoprazole sodium and domperidone in synthetic binary mixtures and human serum.
[Mh] Termos MeSH primário: 2-Piridinilmetilsulfinilbenzimidazóis/análise
Domperidona/análise
Eletrodos
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/química
Domperidona/química
Grafite/química
Seres Humanos
Oxirredução
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 5587267Z69 (Domperidone); 7782-42-5 (Graphite); D8TST4O562 (pantoprazole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE


  9 / 3559 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28378028
[Au] Autor:Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF
[Ad] Endereço:Department of Medical Biophysics, University Health Network, University of Toronto, Toronto, ON, Canada. susie.tan@uhnres.utoronto.ca.
[Ti] Título:Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity.
[So] Source:Cancer Chemother Pharmacol;79(5):959-969, 2017 May.
[Is] ISSN:1432-0843
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Autophagy is a survival mechanism that allows recycling of cellular breakdown products, particularly in stressed cells. Here we evaluate the hypotheses that up-regulation of autophagy is a common mechanism of resistance to chemotherapy, and that drug resistance can be reversed by inhibiting autophagy with a proton pump inhibitor. METHODS: We exposed human PC3, LNCaP and MCF7 cells to seven clinically-used chemotherapy drugs ± pantoprazole, examined the up-regulation of autophagy and the effect on cellular proliferation by Western Blots, MTS assay and colony-forming assay. The distribution of drug effects and of autophagy was quantified in LNCaP tumor sections in relation to blood vessels and hypoxia by immunohistochemistry using γH2AX, cleaved caspase-3 and p62. RESULTS: All anticancer drugs led to up-regulation of autophagy in cultured tumor cells. Pantoprazole inhibited the induction of autophagy in a time- and dose-dependent manner, and sensitized cancer cells to the seven anti-cancer drugs. Treatment of LNCaP xenografts with paclitaxel induced both DNA damage and autophagy; autophagy was inhibited and markers of toxicity were increased by pantoprazole. CONCLUSIONS: Induction of autophagy is a general mechanism associated with resistance to anticancer drugs and that its inhibition is a promising therapeutic strategy to enhance the effects of chemotherapy and improve clinical outcomes.
[Mh] Termos MeSH primário: 2-Piridinilmetilsulfinilbenzimidazóis/farmacologia
Antineoplásicos/uso terapêutico
Autofagia/efeitos dos fármacos
Resistência a Medicamentos Antineoplásicos/efeitos dos fármacos
Inibidores da Bomba de Prótons/farmacologia
[Mh] Termos MeSH secundário: Antineoplásicos Fitogênicos/farmacologia
Vasos Sanguíneos/efeitos dos fármacos
Linhagem Celular Tumoral
Proliferação Celular
Relação Dose-Resposta a Droga
Seres Humanos
Hipóxia/patologia
Paclitaxel/farmacologia
Microambiente Tumoral/efeitos dos fármacos
Ensaio Tumoral de Célula-Tronco
Regulação para Cima/efeitos dos fármacos
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Antineoplastic Agents); 0 (Antineoplastic Agents, Phytogenic); 0 (Proton Pump Inhibitors); D8TST4O562 (pantoprazole); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170406
[St] Status:MEDLINE
[do] DOI:10.1007/s00280-017-3298-5


  10 / 3559 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28370240
[Au] Autor:Jiao H; Li Y; Sun L; Zhang H; Yu L; Yu L; Yuan Z; Xie L; Chen J; Wang Y
[Ad] Endereço:Research Division of Clinical Pharmacology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
[Ti] Título:A chiral LC-MS/MS method for the enantioselective determination of R-(+)- and S-(-)-pantoprazole in human plasma and its application to a pharmacokinetic study of S-(-)-pantoprazole sodium injection.
[So] Source:Biomed Chromatogr;31(10), 2017 Oct.
[Is] ISSN:1099-0801
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Pantoprazole, a proton pump inhibitor, is clinically used for the treatment of peptic diseases. An enantioselective LC-MS/MS method was developed and validated for the simultaneous determination of pantoprazole enantiomers in human plasma. Pantoprazole enantiomers and the internal standard were extracted from plasma using acetonitrile. Chiral separation was carried on a Chiralpak IE column using the mobile phase consisted of 10 mm ammonium acetate solution containing 0.1% acetic acid-acetonitrile (28 : 72, v/v). MS analysis was performed on an API 4000 mass spectrometer. Multiple reactions monitoring transitions of m/z 384.1→200.1 and 390.1→206.0 were used to quantify pantoprazole enantiomers and internal standard, respectively. For each enantiomer, no apparent matrix effect was found, the calibration curve was linear over 5.00-10,000 ng/mL, the intra- and inter-day precisions were below 10.0%, and the accuracy was within the range of -5.6% to 0.6%. This method was applied to the stereoselective pharmacokinetic studies in human after intravenous administration of S-(-)-pantoprazole sodium injections. No chiral inversion was observed during sample storage, preparation procedure and analysis. While R-(+)-pantoprazole was detected in human plasma with a slightly high concentration, which implied that S-(-)-pantoprazole may convert to R-(+)-pantoprazole in some subjects.
[Mh] Termos MeSH primário: 2-Piridinilmetilsulfinilbenzimidazóis/sangue
2-Piridinilmetilsulfinilbenzimidazóis/farmacocinética
Cromatografia Líquida/métodos
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem
2-Piridinilmetilsulfinilbenzimidazóis/química
Administração Intravenosa
Adolescente
Adulto
Estabilidade de Medicamentos
Feminino
Seres Humanos
Limite de Detecção
Modelos Lineares
Masculino
Reprodutibilidade dos Testes
Estereoisomerismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); D8TST4O562 (pantoprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1002/bmc.3980



página 1 de 356 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde